Welltower
WELL
$235.63
-2.26%
Welltower Inc. is a real estate investment trust (REIT) that owns a diversified portfolio of approximately 2,800 healthcare properties, including senior housing, medical office, and skilled nursing facilities across the U.S., Canada, and the U.K. As one of the largest healthcare REITs by market capitalization, it distinguishes itself through a focus on high-quality, operationally intensive assets in mature healthcare markets. The current investor narrative centers on the company's accelerating revenue growth driven by strong senior housing demand and strategic acquisitions, while the stock has rallied sharply amid a broader real estate rebound and expectations of continued Fed rate cuts.…
WELL
Welltower
$235.63
Related headlines
Investment Opinion: Should I buy WELL Today?
Rating: Hold. Welltower's strong growth and improving profitability are offset by a premium valuation that already prices in much of the optimism. The consensus analyst rating is Buy with an average target of $243.50, implying -3.4% downside from the current price, suggesting the stock is fairly valued to slightly overvalued.
Supporting Evidence: Revenue growth accelerated to 38.4% YoY in Q1 2026, net margin expanded to 22.0% from 10.8%, and free cash flow TTM is $2.54B. However, the trailing P/E of 131.6x is well above the historical median of ~96x, and the forward P/E of 75.0x still implies high expectations. The EV/EBITDA of 60.5x is elevated relative to typical healthcare REIT levels. The stock's 56.2% one-year gain has outpaced the S&P 500's 16.5%, and it now trades above the average analyst target.
Risks & Conditions: The Hold rating would upgrade to Buy if the forward P/E compresses below 50x or if revenue growth sustains above 30% with margin expansion. It would downgrade to Sell if revenue growth decelerates below 20% or if interest rates rise significantly, compressing REIT multiples. Overall, Welltower appears overvalued relative to its history and peers, but the strong operational momentum justifies a neutral stance for now.
Sign up to view all
WELL 12-Month Price Forecast
Welltower's fundamentals are strong with accelerating growth and improving margins, but the stock's premium valuation and price above the average analyst target suggest limited upside. The base case of moderate growth and stable valuation is most likely, with a 50% probability. Upside catalysts (rate cuts, strong earnings) could drive the stock to $280, while downside risks (rate hikes, slowdown) could pull it to $192. The neutral stance reflects the balanced risk/reward at current levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Welltower's 12-month outlook, with a consensus price target around $249.36 and implied upside of +5.8% versus the current price.
Average Target
$249.36
0 analysts
Implied Upside
+5.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$192 - $280
Analyst target range
Welltower is covered by 22 analysts, with a consensus recommendation of 'Buy' (mean score 1.73 on a 1-5 scale where 1 is Strong Buy). The average price target is $243.50, implying a -3.4% downside from the current price of $252.07. The distribution shows a bullish tilt, but the average target below the current price suggests the stock has run ahead of fundamental expectations. The target range spans from $192.00 (low) to $280.00 (high). The high target of $280 implies 11.1% upside and likely assumes continued strong execution and multiple expansion. The low target of $192 implies a 23.8% downside, reflecting risks such as rising interest rates or slower growth. Recent rating actions show upgrades: JP Morgan moved to Neutral from Overweight, while Evercore, Wells Fargo, and RBC have upgraded to Outperform/Overweight. This positive momentum in ratings supports the bullish narrative, but the wide spread between low and high targets ($88) indicates high uncertainty about the stock's trajectory.
Bulls vs Bears: WELL Investment Factors
Welltower presents a compelling growth story with accelerating revenue, expanding margins, and a healthy balance sheet, supported by positive analyst upgrades. However, the stock trades at a premium valuation (trailing P/E 131.6x) and above the average analyst target, leaving limited upside. The key tension is whether the rapid earnings growth can justify the elevated multiple; if growth decelerates, the stock could face significant downside. Currently, the bull case has stronger evidence given the fundamental momentum, but valuation risk tempers enthusiasm.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 38.4% YoY to $3.31B, accelerating from 25.1% in Q2 2025 and 18.8% in Q1 2025, driven by strong senior housing demand and acquisitions.
- Expanding Profit Margins: Net margin improved to 22.0% in Q1 2026 from 10.8% a year ago, while operating margin rose to 16.9% from 15.8%, reflecting operational leverage and cost control.
- Strong Balance Sheet and Liquidity: Debt-to-equity is a conservative 0.51, and the current ratio of 5.34 indicates ample short-term liquidity, reducing financial distress risk.
- Positive Analyst Momentum: Recent upgrades from Evercore, Wells Fargo, and RBC to Outperform/Overweight support bullish sentiment, with 22 analysts giving a consensus Buy rating.
Bearish
- Premium Valuation: Trailing P/E of 131.6x and forward P/E of 75.0x are well above historical median of ~96x, implying high growth expectations that may not materialize.
- Stock Above Average Target: Current price of $252.07 exceeds the average analyst target of $243.50, suggesting limited near-term upside and potential overvaluation.
- Interest Rate Sensitivity: As a REIT, Welltower is sensitive to interest rates; a pause or reversal in Fed rate cuts could compress valuations and increase borrowing costs.
- Earnings Volatility: Q4 2025 saw a net loss of $96.4M and negative operating margin of -30.1%, highlighting earnings inconsistency despite the strong Q1 2026 rebound.
WELL Technical Analysis
Welltower is in a sustained uptrend, with the stock up 56.2% over the past year and currently trading at $252.07, near the top of its 52-week range of $158.24 to $252.93 (99.7% of the range). This positioning near highs suggests strong momentum, though it also raises caution about potential overextension. The 1-year relative strength versus SPY is +39.7%, indicating significant outperformance. Short-term momentum is accelerating: the 1-month price change is +13.8% and the 3-month change is +20.8%, both far outpacing the S&P 500's +0.8% and +3.5% over the same periods. This divergence from the broader market signals strong stock-specific catalysts, likely tied to sector rotation into REITs and positive earnings momentum. The 1-month relative strength of +13.1% confirms the stock is leading. The 52-week high of $252.93 serves as immediate resistance; a breakout above this level would signal continued upside toward analyst high targets of $280. Support lies at the 52-week low of $158.24, though the stock is far above that. With a beta of 0.763, Welltower is less volatile than the overall market, which may appeal to risk-averse investors but also means it may lag during sharp market rallies.
Beta
0.76
0.76x market volatility
Max Drawdown
-12.6%
Largest decline past year
52-Week Range
$161-$255
Price range past year
Annual Return
+41.6%
Cumulative gain past year
| Period | WELL Return | S&P 500 |
|---|---|---|
| 1m | +3.8% | -0.7% |
| 3m | +8.6% | +2.9% |
| 6m | +25.1% | +7.2% |
| 1y | +41.6% | +16.9% |
| ytd | +26.0% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WELL Fundamental Analysis
Revenue growth is robust and accelerating: Q1 2026 revenue of $3.31 billion grew 38.4% year-over-year, up from 25.1% growth in Q2 2025 and 18.8% in Q1 2025. The trailing twelve-month revenue reached $11.38 billion, driven by strong performance in senior housing and management service revenue of $2.78 billion. This acceleration is a key positive for the investment case, signaling successful execution of acquisition and operational strategies. Profitability has improved markedly: net income in Q1 2026 was $728.7 million, up from $257.9 million in Q1 2025, with net margin expanding to 22.0% from 10.8%. Gross margin remained stable at 37.8%, while operating margin improved to 16.9% from 15.8% a year ago. The company is solidly profitable with EPS of $1.04 in Q1 2026, compared to $0.40 in the prior-year quarter. The balance sheet is healthy: debt-to-equity is 0.51, and the current ratio is 5.34, indicating ample liquidity. Free cash flow TTM is $2.54 billion, providing strong internal funding for growth and dividends. ROE is 2.2%, which is low but typical for REITs due to high asset bases; the improving trend is encouraging.
Quarterly Revenue
$3.3B
2026-03
Revenue YoY Growth
+38.4%
YoY Comparison
Gross Margin
37.8%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WELL Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 131.6x, while the forward P/E is 75.0x, implying the market expects significant earnings growth. The wide gap between trailing and forward multiples suggests investors are pricing in a sharp earnings recovery, consistent with the recent margin expansion. Compared to the industry, Welltower trades at a premium: the P/S ratio of 11.6x is above the sector median (data not provided, but healthcare REITs typically trade around 8-10x sales). The EV/EBITDA of 60.5x is also elevated, reflecting the market's willingness to pay for growth and quality. Historically, Welltower's trailing P/E has ranged from 43x to 331x over the past five quarters. The current 131.6x is above the median of ~96x, indicating the stock is on the higher end of its historical valuation band. This suggests the market is pricing in optimistic future growth, which could leave the stock vulnerable if results disappoint.
PE
131.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 43x~172x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
60.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Welltower's debt-to-equity of 0.51 is manageable, but interest expense of $192.7M in Q1 2026 (up from $144.9M a year ago) could pressure earnings if rates stay high. The Q4 2025 operating loss of -$943.7M and net loss of $96.4M demonstrate earnings volatility, partly due to non-cash impairments. Free cash flow of $2.54B TTM provides a cushion, but the payout ratio of 200% indicates dividends exceed earnings, which is unsustainable without continued growth. Revenue concentration in senior housing (subject to occupancy and labor costs) adds operational risk.
Market & Competitive Risks: The stock's beta of 0.763 suggests lower market correlation, but its premium valuation (P/S 11.6x vs. sector median ~8-10x) makes it vulnerable to multiple compression if growth slows. Competitive pressures from other healthcare REITs and rising construction of new senior housing could pressure occupancy and rental rates. Regulatory changes in healthcare reimbursement or property taxes could impact profitability. The recent rally (+56.2% YoY) has outpaced fundamentals, increasing the risk of a correction.
Worst-Case Scenario: A sharp rise in interest rates, combined with a slowdown in senior housing demand or a recession, could trigger earnings misses and multiple compression. In such a scenario, the stock could fall to the 52-week low of $158.24, representing a -37.2% decline from the current price of $252.07. This would imply a P/E closer to 80x trailing earnings, still elevated but reflecting severe pessimism.
FAQ
The key risks are: 1) Valuation risk: trailing P/E of 131.6x leaves the stock vulnerable to multiple compression if growth disappoints. 2) Interest rate risk: as a REIT, higher rates increase borrowing costs and reduce property values; a 50 bps rate hike could pressure the stock. 3) Operational risk: Q4 2025 showed a net loss of $96.4M, highlighting earnings volatility. 4) Competitive risk: new senior housing supply could pressure occupancy and rental rates. The most severe risk is a -37.2% decline to the 52-week low of $158.24 if a recession hits.
The 12-month forecast is mixed. The bull case (25% probability) sees the stock reaching $260-$280, driven by sustained growth and rate cuts. The base case (50% probability) targets $230-$260, with growth moderating and the stock near the average analyst target of $243.50. The bear case (25% probability) sees a decline to $192-$230 if interest rates rise or growth slows. The most likely scenario is the base case, with the stock trading in a range around current levels.
Welltower appears overvalued relative to its history and peers. The trailing P/E of 131.6x is above the five-quarter median of ~96x, and the forward P/E of 75.0x still implies high growth expectations. The P/S ratio of 11.6x is above the typical healthcare REIT range of 8-10x. The market is pricing in continued strong earnings growth, which is supported by recent trends but leaves little room for error. The stock's current price above the average analyst target further suggests overvaluation.
Welltower is a good buy for investors with a long-term horizon who believe in the senior housing growth story and can tolerate valuation risk. The stock offers strong revenue growth (38.4% YoY) and improving margins, but the trailing P/E of 131.6x is elevated. The average analyst target of $243.50 implies a -3.4% downside from the current price of $252.07, suggesting limited near-term upside. The biggest risk is multiple compression if growth slows. For growth-oriented investors, it may be a hold; for value investors, it is likely overvalued.
Welltower is more suitable for long-term investment due to its growth trajectory and lower volatility (beta 0.763). The stock has rallied 56.2% over the past year, but short-term upside is limited given the premium valuation and price above the average analyst target. Long-term investors can benefit from demographic trends in senior housing and potential dividend growth (current yield 1.52%). A minimum holding period of 3-5 years is recommended to ride out interest rate cycles and allow earnings to catch up with the valuation.